Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Associa Real Property Management Named Largest Residential 2-02-2023, 20:10

Axi Select Traders Share Their Experience So Far on Axi’s Capital Allocation Program in New Podcast Series Axi Select Talks 8-08-2024, 18:00